Absorption Systems, a US company specialising in Absorption, Distribution, Metabolism and Excretion (ADME) assays for small-molecule drug candidates, has boosted its testing capabilities by acquiring San Diego-based Perry Scientific for an undisclosed sum.

Described as “the oldest and largest contract research organisation (CRO) in Southern California”, Perry Scientific was set up in 1999 to conduct preclinical studies for the pharmaceutical and biotechnology industries, including toxicology testing and central nervous system pharmacology. According to the former’s founder Dr Andrew Perry, the Perry Scientific and Absorption Systems businesses are “entirely complementary”.

For Absorption Systems, the deal “furthers our mission to efficiently move from the early stages of drug discovery testing for ADME and pharmacokinetics through the definitive safety and toxicology testing necessary for new drug and device submissions”, said president and chief executive officer Patrick Dentinger.

The combined entity will be the only CRO in Southern California that can offer a full range of pharmacokinetic and toxicology studies, including the dose vehicle development and the optimisation, dosing and analytical phases of those studies, Absorption Systems noted.